Primary Sclerosing Cholangitis in Inflammatory Bowel Disease: A 20-Year Cohort Study of Clinical Features and Transplant-Free Survival
Digestive Diseases · 2026-11-07
DOI: 10.1159/ddi/acnag018 ↗Abstract
Abstract Objective: To evaluate prevalence, clinical characteristics, and long-term liver-related outcomes of primary sclerosing cholangitis (PSC) in patients with inflammatory bowel disease (IBD), focusing on determinants of transplant-free survival. Methods: In this retrospective cohort study, 2,376 patients with IBD were screened over 20 years, and 30 patients with PSC were identified. A matched IBD control group without PSC (n=90) was included for comparison. Clinical features, biochemical parameters, and liver-related outcomes were analyzed. Transplant-free survival was assessed using Kaplan–Meier analysis, and exploratory univariable Cox regression was performed to identify predictors of liver transplantation. Results: PSC was identified in 1.3% of patients and was more frequently associated with ulcerative colitis. Large-duct PSC accounted for 87% of cases, and cirrhosis was present in 20% at diagnosis. During median follow-up of 60 months, liver transplantation occurred in 27% of patients. Baseline cirrhosis was strongly associated with reduced transplant-free survival (log-rank p=0.002) and increased risk of liver transplantation (HR 6.05, 95% CI 1.49–24.61). Median transplant-free survival was 4 years in cirrhotic patients, whereas it was not reached in non-cirrhotic patients. Biochemical response to ursodeoxycholic acid (UDCA) was not associated with transplantation or mortality. Compared with controls, PSC–IBD patients more frequently exhibited extensive colitis and backwash ileitis, while treatment exposure and remission rates were similar. Conclusion: PSC is a clinically relevant but uncommon comorbidity in IBD. Baseline cirrhosis emerged as the primary determinant of adverse liver-related outcomes, whereas biochemical response to UDCA was not prognostically informative. These findings suggest that disease stage at diagnosis, rather than biochemical response, should guide risk stratification and clinical decision-making in PSC.
EUVIMED